Gilead Sciences to settle HIV drug dispute with GSK in 1.25 billion USD
GlaxoSmithKline plc announced that ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi & Co. Limited Shionogi as shareholders, has agreed to settle the global patent infringement litigation between GSK, Shionogi and Gilead Sciences, Inc. Gilead concerning ViiV Healthcares patents relating to dolutegravir, an antiretroviral medication used, together with other medicines, to treat human immunodeficiency virus.